FIG. 3.

Specificity of NiV- and HeV-mediated fusion. Effector cells were prepared as described in the legend to Fig. 2. Human U373 cells were infected with the reporter vaccinia virus vCB21R encoding E. coli lacZ (target cells). Peptides or a rabbit polyclonal anti-NiV serum were diluted and added to the glycoprotein-expressing cells (10⁵) in a 96-well plate, and U373 cells were then added (10⁵). Each peptide and serum concentration was tested in duplicate in 96-well-plate format. After 3 h at 37°C, Nonidet P-40 was added and β-Gal activity was quantitated. (A) Inhibition of HeV-mediated fusion by synthetic C-terminal F peptides. (B) Inhibition of NiV-mediated fusion by synthetic C-terminal F peptides. (C) Inhibition of NiV-mediated fusion by an anti-NiV antiserum.